IBio Reports Q3 Results
iBio Inc | 10-Q: Quarterly report
IBio Q3 EPS $(0.71) Up From $(9.53) YoY
iBio (AMEX:IBIO) reported quarterly losses of $(0.71) per share. This is a 92.55 percent increase over losses of $(9.53) per share from the same period last year.
IBio 3Q Rev $0 >IBIO
IBio 3Q Rev $0 >IBIO
Press Release: IBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update -- Strengthened cash position with investment by healthcare specialist investors -- Expanding into c
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
IBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders
IBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders
IBio Inc. Raises $15M in Private Placement and Issues Warrants
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
Top Midday Gainers
iBio's (IBIO) shares were up 211% amid heavy trading Wednesday, a day after the company said it signed a securities purchase agreement for a private investment in public equity financing with expected
SMR, GCTS and GSIW Among Mid-day Movers
IBio Climbs After AI-led Drug Discovery Deal
IBio Shares Double After Collaboration Agreement With AstralBio
iBio shares doubled after the company entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.
Micro-Cap Stock IBio Doubles On Wednesday - Here's Why
iBio Inc (NYSE:IBIO) shares are surging after the company entered into a collaboration agreement with AstralBio Inc. on Wednesday to discover, engineer, and develop antibodies to treat obesity and oth
IBio, ImmunityBio, Mesoblast Among Healthcare Movers
Market-Moving News for March 27th
IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.DRCT: -49% | Direct Digital Holdings s
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings
US stock futures were trending higher in Wednesday's premarket session ahead of a relatively quiet day on the economic calendar as many investors are likely looking ahead to tomorrow's jobless claims
Top Premarket Gainers
MariaDB (MRDB) shares surged 82% in recent Wednesday premarket activity a day after Progress Software (PRGS) said it is looking into a possible offer to acquire MariaDB at $0.60 per share. iBio (IBIO)
IBio and AstralBio Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop
No Data